Company / Financials
Immunocore Holdings plc Financials
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$400.0M
FY2025 · +29.0% YoY
Net Income
-$35.5M
FY2025 · +30.5% YoY
Profit Margin
-8.9%
FY2025 · net income / revenue
ROE
-9.3%
FY2025 · return on equity
Total Assets
$1.1B
FY2025
Total Debt
-
FY2025
Equity
$381.0M
FY2025
ROA
-3.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$400.0M+29.0% YoYNet Income HistoryProfit after all expenses and taxes-$35.5M+30.5% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$5.1M+86.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$45.4M+35.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$165.4M+6.2% YoYR&D Expense HistoryResearch and development spending$274.9M+23.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$12.2M-35.4% YoYIncome Tax HistoryTotal income tax expense$16.4M+987.2% YoYEPS (Basic) HistoryBasic earnings per share-$1.13+1.7% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.13+1.7% YoY